Literature DB >> 21107661

Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models.

Wojciech Krzyzanski1.   

Abstract

Transit compartments (TC) models are used to describe pharmacodynamic responses that involve drug action on cells undergoing differentiation and maturation. Such pharmacodynamic systems can also be described by lifespan based indirect response (LIDR) models. The purpose of this report is to investigate conditions under which the transit compartments models can be considered a special case of LIDR models. An integral representation of a solution to TC model has been used to determine the lifespan distribution for cell population described by this model. The distribution served as a basis for definition of new LIDRE (lifespan based indirect response with an effect on the lifespan distribution) models. Time courses of responses described by both types of models were simulated for a monoexponential pharmacokinetic function. The limit response was calculated as the number of transit compartments approached infinity. The difference between the limit response and TC responses were evaluated by computer simulations using MATLAB 7.7. TC models are a special case of LIDR models with the lifespan distribution described by the gamma function. If drug affects only the production of cells, then the cell lifespan distribution is time invariant. In this case an increase in the number of compartments results in a basic LIDR model with a point lifespan distribution. When the drug inhibits or stimulates cell aging, the cell lifespan distribution becomes time dependent revealing a new mechanism for drug effect on the gamma probability density function. The TC model with a large number of transit compartments converges to an LIDRE model. The limit LIDR models are approximated by the TC models when the number of compartments is at least 5. A moderate improvement in the approximation is observed if this number exceeds 20. The lifespan distribution for a cell population described by a TC model is described by the gamma probability density function. A drug affects this distribution only if it stimulates or inhibits the rate of cell maturation. If the number of transit compartments increases, then the TC model converges to a new type of LIDR model.

Entities:  

Mesh:

Year:  2010        PMID: 21107661      PMCID: PMC3177953          DOI: 10.1007/s10928-010-9183-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  25 in total

Review 1.  Pharmacodynamic modeling of time-dependent transduction systems.

Authors:  D E Mager; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  2001-09       Impact factor: 6.875

Review 2.  Mechanistic models for myelosuppression.

Authors:  Lena E Friberg; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

3.  Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Authors:  Yow-Ming C Wang; Wojciech Krzyzanski; Sameer Doshi; Jim J Xiao; Juan Jose Pérez-Ruixo; Andrew T Chow
Journal:  AAPS J       Date:  2010-10-21       Impact factor: 4.009

4.  A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep.

Authors:  S H Chapel; P Veng-Pedersen; R L Schmidt; J A Widness
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

5.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

Authors:  Lena E Friberg; Anja Henningsson; Hugo Maas; Laurent Nguyen; Mats O Karlsson
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

6.  The estimation of blood platelet survival. I. General principles of the study of cell survival.

Authors:  E A Murphy; M E Francis
Journal:  Thromb Diath Haemorrh       Date:  1969-11-15

7.  The estimation of blood platelet survival. II. The multiple hit model.

Authors:  E A Murphy; M E Francis
Journal:  Thromb Diath Haemorrh       Date:  1971

8.  Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.

Authors:  Wojciech Krzyzanski; Pawel Wiczling; Phil Lowe; Etienne Pigeolet; Martin Fink; Alexander Berghout; Sigrid Balser
Journal:  J Clin Pharmacol       Date:  2010-09       Impact factor: 3.126

9.  Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.

Authors:  Monica Simeoni; Paolo Magni; Cristiano Cammia; Giuseppe De Nicolao; Valter Croci; Enrico Pesenti; Massimiliano Germani; Italo Poggesi; Maurizio Rocchetti
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

Review 10.  Multiple-pool cell lifespan model of hematologic effects of anticancer agents.

Authors:  Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

View more
  25 in total

1.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.

Authors:  Nageshwar R Budha; Andreas Kovar; Bernd Meibohm
Journal:  AAPS J       Date:  2011-10-18       Impact factor: 4.009

3.  General relationship between transit compartments and lifespan models.

Authors:  Gilbert Koch; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-06-23       Impact factor: 2.745

Review 4.  Pharmacodynamic models of age-structured cell populations.

Authors:  Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-16       Impact factor: 2.745

5.  Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model).

Authors:  Jun Shen; Alison Boeckmann; Andrew Vick
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-04       Impact factor: 2.745

6.  A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics.

Authors:  Xiaoying Chen; Timothy Hickling; Eugenia Kraynov; Bing Kuang; Chuenlei Parng; Paolo Vicini
Journal:  AAPS J       Date:  2013-08-30       Impact factor: 4.009

7.  Solution and implementation of distributed lifespan models.

Authors:  Gilbert Koch; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-11-01       Impact factor: 2.745

8.  A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim.

Authors:  Ari Brekkan; Luis Lopez-Lazaro; Gunnar Yngman; Elodie L Plan; Chayan Acharya; Andrew C Hooker; Suresh Kankanwadi; Mats O Karlsson
Journal:  AAPS J       Date:  2018-08-15       Impact factor: 4.009

9.  Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals.

Authors:  Wojciech Krzyzanski; Liviawati Sutjandra; Juan Jose Perez-Ruixo; Bethlyn Sloey; Andrew T Chow; Yow-Ming Wang
Journal:  Pharm Res       Date:  2012-12-19       Impact factor: 4.200

10.  Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin.

Authors:  Carlos Pérez-Ruixo; Belén Valenzuela; José Esteban Peris; Pedro Bretcha-Boix; Vanesa Escudero-Ortiz; José Farré-Alegre; Juan José Pérez-Ruixo
Journal:  AAPS J       Date:  2015-11-17       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.